Quiz Ref ID Multiple sclerosis (MS) is the most frequent chronic demyelinating disease of the central nervous system and a major cause of disability in young adults. It is considered to be an autoimmune disease in which activated lymphocytes enter the central nervous system and trigger an inflammatory cascade that leads to recruitment of other immune cells. This results in demyelination and axonal loss that leads to irreversible neurological deficits. Treatment with interferon beta or glatiramer acetate, the first disease-modifying therapies used to treat MS, improve the natural history of the disease and delay the onset of permanent neurological deficits.
1 Nevertheless, their beneficial effect is partial because they only reduce the relapse rate by about 30%, and their effect on disability progression is more controversial. Quiz Ref ID Natalizumab is a humanized monoclonal antibody directed against the α4 chain of the adhesion molecule VLA-4. It was approved by the US Food and Drug Administration for the treatment of relapsing-remitting MS in 2004. It decreases the relapse rate by up to 68% and the rate of progression of disability by 42%, reducing magnetic resonance imaging (MRI) activity by up to 92%.
2 Post hoc analyses of the pivotal trial (ie, the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis study [AFFIRM]) showed that the proportion of patients with no new or enlarging MRI-detected lesions during the study period was greater in the natalizumab group than in the placebo group.
3 Therefore, disease remission seems an attainable goal for patients with MS who are treated with this new agent, something that the other disease-modifying therapies could not achieve in many cases.
4